138 related articles for article (PubMed ID: 31828320)
21. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.
Ryom L; Dilling Lundgren J; Reiss P; Kirk O; Law M; Ross M; Morlat P; Andreas Fux C; Fontas E; De Wit S; D'Arminio Monforte A; El-Sadr W; Phillips A; Ingrid Hatleberg C; Sabin C; Mocroft A;
J Infect Dis; 2019 Oct; 220(10):1629-1634. PubMed ID: 31504669
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.
Opsomer M; Dimitrova D; Verspeelt J; Purrington A; Mehbob A; Chavers S; Pai H; Vanveggel S; Luo D; Brown K; Moecklinghoff C; Nettles RE; Boven K
Drugs R D; 2018 Sep; 18(3):199-210. PubMed ID: 29992490
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Menshawy A; Ismail A; Abushouk AI; Ahmed H; Menshawy E; Elmaraezy A; Gadelkarim M; Abdel-Maboud M; Attia A; Negida A
Arch Virol; 2017 Aug; 162(8):2181-2190. PubMed ID: 28361290
[TBL] [Abstract][Full Text] [Related]
24. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
Monforte Ad; Reiss P; Ryom L; El-Sadr W; Dabis F; De Wit S; Worm SW; Law MG; Weber R; Kirk O; Pradier C; Phillips AN; Lundgren JD; Sabin CA
AIDS; 2013 Jan; 27(3):407-15. PubMed ID: 23291539
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
26. Contemporary protease inhibitors and cardiovascular risk.
Lundgren J; Mocroft A; Ryom L
Curr Opin Infect Dis; 2018 Feb; 31(1):8-13. PubMed ID: 29232276
[TBL] [Abstract][Full Text] [Related]
27. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Colella E; Ridolfo AL; Galli M; Rusconi S
Antiviral Res; 2016 May; 129():52-57. PubMed ID: 26902109
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Maggi P; Bellacosa C; Leone A; Volpe A; Ricci ED; Ladisa N; Cicalini S; Grilli E; Viglietti R; Chirianni A; Bellazzi LI; Maserati R; Martinelli C; Corsi P; Celesia BM; Sozio F; Angarano G
Atherosclerosis; 2017 Aug; 263():398-404. PubMed ID: 28522147
[TBL] [Abstract][Full Text] [Related]
29. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
[TBL] [Abstract][Full Text] [Related]
32. Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.
Crane HM; Nance RM; Heckbert SR; Ritchings C; Rosenblatt L; Budoff M; Wood BR; Tirschwell DL; Kim HN; Mathews WC; Geng E; Moore RD; Hunt PW; Eron JJ; Burkholder GA; Drozd DR; Chow FC; Becker KJ; Zunt JR; Ho EL; Kalani R; Huffer A; Whitney BM; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):e141-e147. PubMed ID: 31135582
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Jabłonowska E; Pulik P; Kalinowska A; Gąsiorowski J; Parczewski M; Bociąga-Jasik M; Pulik Ł; Siwak E; Wójcik K
J Med Virol; 2017 Dec; 89(12):2122-2129. PubMed ID: 28390164
[TBL] [Abstract][Full Text] [Related]
34. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
Pernas B; Grandal M; Tabernilla A; Cid P; Pértega S; Castro-Iglesias Á; Mena Á; Margusino L; Pedreira JD; Poveda E
J Med Virol; 2016 Dec; 88(12):2125-2131. PubMed ID: 27218208
[TBL] [Abstract][Full Text] [Related]
35. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Majeed SR; West S; Ling KH; Das M; Kearney BP
Antivir Ther; 2019; 24(8):557-566. PubMed ID: 31933482
[TBL] [Abstract][Full Text] [Related]
36. Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?
Metsu D; Toutain PL; Chatelut E; Delobel P; Gandia P
J Antimicrob Chemother; 2017 Sep; 72(9):2407-2409. PubMed ID: 28595364
[TBL] [Abstract][Full Text] [Related]
37. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
[TBL] [Abstract][Full Text] [Related]
38. The use of unboosted darunavir in the setting of ritonavir intolerance: three case reports.
Smith K; Gomes D; Nixon D; Fulco PP
Int J Clin Pharmacol Ther; 2016 Jan; 54(1):52-7. PubMed ID: 26636419
[TBL] [Abstract][Full Text] [Related]
39. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.
Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Ribera E; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Deulofeu R; Perez I; Gatell JM;
Clin Infect Dis; 2015 Mar; 60(5):811-20. PubMed ID: 25389256
[TBL] [Abstract][Full Text] [Related]
40. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
